Mary Steinbach, APRN
Articles
Clinical Scenario: AE Management for Bispecific Therapy in R/R MM
Following the review of a case of a patient with relapsed/refractory multiple myeloma, the panel provides expert perspectives on adverse event management practices.
Adverse Event Management Strategies in GPRC5D Therapy
Experts on multiple myeloma address the intricacies of adverse event management practices, focusing on taste changes and associated weight loss.
Clinical Scenario: AE Management in a Patient with R/R MM on GPRC5D Therapy
Samantha Shenoy, NP, MSN, presents the case of a patient with multiple myeloma and the panel discusses adverse event management practices.
Insights on REMS Programs and Strategies for Effective Patient Care
The panel provides an overview of REMS programs for bispecific therapies in multiple myeloma and discusses how institutions can educate healthcare professionals outside of oncology.
Management and Supportive Care for CRS and ICANS in GPRC5D Therapy
Experts on multiple myeloma discuss prophylactic supportive measures to prevent CRS and ICANS in patients who receive GPRC5D therapy.
Clinical Experience in Managing AEs in GPRC5D Therapy
Mary Steinbach, APRN, shares her experience in managing dysgeusia and nail- and skin-related toxicities seen in patients with multiple myeloma who receive talquetamab.
Clinical Perspective on AE Tolerance
Focusing on patients with multiple myeloma who receive GPRC5D-targeted therapy, Beth Faiman, CNP, PhD, discusses how long-term treatment impacts patients’ tolerance to adverse events.
Administration and Dosing Management
Experts on multiple myeloma offer clinical insights on preparing patients who are going to receive GPRC5D therapy, highlighting step-up and treatment dosing for talquetamab.
Overview of Long-term Follow-up from MonumenTAL-1
Focusing on the MonumenTAL-1 study, Mary Steinbach, APRN, provides clinical insights on nail, skin, and oral toxicities associated with talquetamab.
GPRC5D Therapy: Unique Challenges in Adverse Event Management
Lisa Hwa, APRN, DNP, CNP, FAPO, describes the unique challenges in managing adverse events associated with GPRC5D therapy compared with other bispecifics.
Adverse Event Management with BCMA Therapy
Ellen Marin, PA-C, provides an overview of adverse effects associated with BCMA-directed bispecific therapy in multiple myeloma.
Long-Term Follow-up Overview: MajesTEC-1 and MagnetisMM-3 Recent Data
A panel of experts on multiple myeloma discuss long-term follow-up data from the MajesTEC-1 and MagnetisMM-3 clinical trials.
